International consensus position statement on the role of obesity management medications in the context of metabolic bariatric surgery: expert guideline by the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO)
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Metabolic bariatric surgery (MBS) is the most effective long-term treatment option for clinical obesity and its complications1. Nonetheless, modern pharmacotherapy involving intestinal hormonal analogues, such as semaglutide and tirzepatide, have shown good weight loss outcomes in the short and medium term2–4. Potentially, such obesity management medications (OMMs) may be synergistic with or additive to MBS for selected patients before and/or after MBS regarding improved outcomes. The impact of pharmacotherapy before surgery is unclear, with a lack of high-level evidence regarding the efficacy of preoperative OMMs in reducing intraoperative risks and complications5. Similarly, the evidence is scarce for the use of OMMs as an adjunct therapy to MBS or in patients with a suboptimal initial clinical response or with recurrent weight gain after surgery6–8. For these reasons, the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) asked a multidisciplinary group of international experts in obesity management to develop evidence-based recommendations to serve as a global reference for using OMMs before and after MBS. These recommendations were developed through a Delphi process, identifying areas of expert consensus after a systematic review of the published literature and highlighting areas warranting further research9. Clinical obesity is a condition in which the risk to health associated with excess adiposity has already materialized and can be objectively documented by specific signs and symptoms reflecting biological alterations of tissues and organs that are consistent with extant illness10. In 2023, IFSO created a global consensus to standardize MBS outcomes11, defining a suboptimal initial clinical response and recurrent weight gain as the standard nomenclature. Modern OMMs are the second-generation intestinal hormonal analogues (single or dual analogues), whereas OMMs include all available pharmacotherapy that may be adjunctive to MBS and are not restricted to only modern agents. The core scientific committee (R.V.C., G.P., and L.B.) and the partner organizations—the World Obesity Federation (WOF), the European Association for the Study of Obesity (EASO), and the International Diabetes Federation (IDF)—tasked a multidisciplinary group of 40 international authorities to develop evidence-based recommendations. Voting experts were entirely chosen from academia, without representatives from industry. The names and details of these experts, as well as those of an internationally recognized Delphi expert (R.L.), with knowledge of endocrinology and metabolism, and a patient representative, are provided in the Collaborators section. The preset research questions for the systematic review of evidence included preoperative and postoperative use of pharmacotherapy, the class of drugs employed, the impact on weight and obesity-related complications, and the effectiveness and complications of using medications before and after MBS. Given the objectives of the consensus conference, the relatively short duration of availability and clinical use of modern pharmacotherapy, and the heterogeneous publications on the use of other OMMs, it was decided to adopt a relatively low threshold for the selection of evidence, including not only RCTs but also published systematic reviews and observational studies. A document with the results of this systematic review was circulated among the whole group in preparation for the Delphi process. The core scientific committee prepared a list of issues for each statement and a first draft of the rationale for each statement was sent to the experts before the start of the Delphi process. Furthermore, each expert was asked to contribute three to four statements within their field of expertise. The statements were then revised by the core scientific committee and by the Delphi expert. An initial Delphi process, referred to as the online Delphi process, was conducted by e-mail among the full expert panel, beginning on 25 March 2024. The patient representative was not involved in the online Delphi process. Each expert returned their completed questionnaire to the Delphi expert without sharing their votes or comments with the other expert panel members. The second part of the Delphi process was conducted as a 2-day in-person meeting, with the full voting expert panel and the patient representative, without voting capacity, but actively involved in the discussions, from 30 April 2024 to 1 May 2024, in Vienna, Austria. The first day consisted of expert presentations and a discussion of the available evidence on using OMMs and MBS. All experts who submitted statements for the Delphi voting presented the topics related to their statements to the entire group before the open discussion. The voting took place on the second day of the in-person meeting. The core scientific committee divided the topics for discussion and voting into three modules: module 1, common understan
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2301972 · Cited by 1,174
Self-citationWilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B. M., Oral, T. K., Rosenstock, J., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14725 · Cited by 1,128
Sjöström, L., Peltonen, M., Jacobson, P., Ahlin, S., Andersson-Assarsson, J., Anveden, Å., Bouchard, C., Carlsson, B., Karason, K., Lönroth, H., et al. (2014) · JAMA · doi:10.1001/jama.2014.5988 · Cited by 1,054
Self-citationObesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation
Lingvay, I., Sumithran, P., Cohen, R. V., & le Roux, C. W. (2022) · The Lancet · doi:10.1016/s0140-6736(21)01919-x · Cited by 581
Self-citationMok, J., Adeleke, M. O., Brown, A., Magee, C. G., Firman, C., Makahamadze, C., Jassil, F. C., Marvasti, P., Carnemolla, A., Devalia, K., et al. (2023) · JAMA Surgery · doi:10.1001/jamasurg.2023.2930 · Cited by 178
Lancet Diabetes & Endocrinology Commission on the Definition and Diagnosis of Clinical Obesity
Rubino, F., Batterham, R. L., Koch, M., Mingrone, G., le Roux, C. W., Farooqi, I. S., Farpour-Lambert, N., Gregg, E. W., & Cummings, D. E. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00058-x · Cited by 126
Self-citationEfficacy of adjuvant weight loss medication after bariatric surgery
Nor Hanipah, Z., Nasr, E. C., Bucak, E., Schauer, P. R., Aminian, A., Brethauer, S. A., & Cetin, D. (2018) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2017.10.002 · Cited by 93
Self-citationMurvelashvili, N., Xie, L., Schellinger, J. N., Mathew, M. S., Marroquin, E. M., Lingvay, I., Messiah, S. E., & Almandoz, J. P. (2023) · Obesity · doi:10.1002/oby.23736 · Cited by 86
Cost-effectiveness analysis of 4 GLP-1RAs in the treatment of obesity in a US setting
Hu, Y., Zheng, S.-L., Ye, X.-L., Shi, J.-N., Zheng, X.-W., Pan, H.-S., Zhang, Y.-W., Yang, X.-L., & Huang, P. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-200 · Cited by 45
Istfan, N. W., Anderson, W. A., Hess, D. T., Yu, L., Carmine, B., & Apovian, C. M. (2020) · Obesity · doi:10.1002/oby.22786 · Cited by 43
Cited by
Nadolsky, K., Garvey, W. T., Agarwal, M., Bonnecaze, A., Burguera, B., Chaplin, M. D., Griebeler, M. L., Harris, S. R., Schellinger, J. N., Simonetti, J., et al. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.07.017 · Cited by 141
Obesity Treatment With Bariatric Surgery vs GLP-1 Receptor Agonists
Barrett, T. S., Hafermann, J. O., Richards, S., LeJeune, K., & Eid, G. M. (2025) · JAMA Surgery · doi:10.1001/jamasurg.2025.3590 · Cited by 87
Stoll, F., Kantowski, T., Laaser, J., Kloiber, U., Plitzko, G., Mann, O., Aberle, J., & Lautenbach, A. (2025) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2025.02.004 · Cited by 20
Dobbie, L. J., Tolvanen, L., Alves, D., Baker, J. L., Bez, N. S., Birney, S., Bogl, L. H., Brown, A., Bullo, M., Clare, K., et al. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00122-1 · Cited by 8
Self-citation
Metadata
- Authors
- Cohen, R. V., Busetto, L., Levinson, R., Le Roux, C. W., Salminen, P., Prager, G., Surgery, I. C. O. T. R. O. O. M. M. I. T. C. O. M. B., Aminian, A., Blüher, M., Carlsson, L., Cohen, R. V., Cummings, D., Gawdat, K., Haddad, M., Halford, J., Ji, L., Kaplan, L., Kow, L., Lakdawala, M., Leite, S., Levinson, R., Mooney, V., O’Kane, M., Parmar, C., Ponce, J., Prager, G., Salas, X. R., Schauer, P., Schroeder, A., Shikora, S., Suliman, S., Tham, K. W., Petry, T. B. Z., Al Faris, N., Busetto, L., Di Lorenzo, N., Dicker, D., Kermansaravi, M., Kurian, M., Le Roux, C. W., Nimeri, A., Perretta, S., Poggi, L., Rubino, F., Salminen, P., Schwarz, P., Sharma, A., Suter, M., & Vidal, J.
- Venue
- British Journal of Surgery
- Publisher
- Oxford University Press (OUP)
- Published
- 2024-11-27
- Volume
- 111
- Issue
- 12
- ISSN
- 0007-1323 (ISSN-L)
- 1365-2168
- OpenAlex
- W4404878875
- Cited by
- 52
- References
- 13
- FWCI
- 19.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.